Candriam Equities L Biotechnology Class I GBP Cap
Category Sector Equity Biotechnology
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price
£5,369.85
£-104.92 (-1.92%)
Fund Code
CDBIA
BDBB972
LU1269737059
Prices updated as at 12 Nov 2026
Prices in GBP
Investment objective
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund.
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide or Product Summary document
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Growth
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk & rating
- Management
| Fund status | Open |
| Fund type | SICAV |
| Fund manager | Linden Thomson, Servaas Michielssens |
| 5740.61 | |
| 4367.22 | |
| Fund comparative index | NASDAQ Biotechnology TR USD |
| Specialist | |
| - | |
| 0.83 | |
| 0.18 | |
| 0.00 | |
| Sector Equity Biotechnology | |
| 20 | |
| Fund provider | Candriam |
| Share class launch date | 08 Mar 2016 |
| £1.44b | |
| - | |
| - | |
| - | |
| - |
Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.